Merry J Markham

Merry J Markham, MD, FACP FASCO

Chief, Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832

About Merry J Markham

Merry Jennifer Markham, MD, FACP, FASCO, professor of medicine, is chief of the division of hematology and oncology within the department of medicine and serves as the associate director for medical affairs at the UF Health Cancer Center. She is the research lead for the UFHCC’s Gynecologic Cancers Disease Site Group. She is the principal investigator for all chemotherapeutic and investigational therapy trials for gynecologic cancers and is site PI for all Gynecologic Oncology Group/NRG Oncology gynecologic cancer trials. Dr. Markham earned her medical degree at the University of Miami Miller School of Medicine and then completed her residency in internal medicine at UF where she served as chief medical resident and later completed a fellowship in hematology and oncology. Clinically, Dr. Markham’s primary focus is on the care of women with gynecologic malignancies. Her research is focused on investigations of experimental therapeutics and prognostic factors for gynecologic malignancies. Dr. Markham is also involved in the study of quality of cancer care, quality improvement strategies and cancer survivorship. Dr. Markham is board-certified in medical oncology. She is also a member of the American Society of Clinical Oncology, the American College of Physicians, the Society of Gynecologic Oncology and several clinical trial cooperative groups.

Related Links:

Accomplishments

Fellow of the American Society of Clinical Oncology (FASCO)
2020 · American Society of Clinical Oncology
Hematology/OncologyFellowship Positive Impact Award
2015 · University of Florida
College of Medicine Exemplary Teacher Award
2011-2019 · University of Florida
Award for Excellence in Teaching Medical Students
2009-2010 · University of Florida

Teaching Profile

Courses Taught
2014-2018
MDT7200 Elect Top/Medicine
2016
MDC7200 Medicine Clerkship

Board Certifications

  • Oncology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Medicine
Subspecialties
  • Hematology
  • Hematology and Oncology
  • Oncology
Areas of Interest
  • Cancer – resources
  • Cervical cancer
  • Endometrial cancer
  • Gynecological Cancer
  • Ovarian cancer

Research Profile

Dr. Markham focuses her clinical expertise and investigations on gynecologic malignancies. She serves as the Program Leader for the multidisciplinary Gynecologic Oncology Program at UF and the Research Lead for the UF Health Cancer Center’s Gynecologic Cancers Disease Site Group. Highly involved in medical education, Dr. Markham has been a medical school course director and is a frequent lecturer in the College of Medicine. She serves as a mentor and teacher of medical students, residents, and hematology-oncology fellows in the Department of Medicine, and she has received numerous awards for her teaching activities. Dr. Markham’s research interests include – experimental therapeutics and prognostic factors for gynecological malignancies; quality of cancer care and quality improvement strategies; and cancer communications, including the role of social media in medicine, patient education, patient decision making and empowerment, and medical education.

Open Researcher and Contributor ID (ORCID)

0000-0003-3567-3494

Publications

2022
Administration of Immune Checkpoint Inhibitors Near the End of Life
JCO Oncology Practice. 18(6):e849-e856 [DOI] 10.1200/op.21.00689.
2022
Cancer patients’ satisfaction with telehealth during the COVID-19 pandemic.
PloS one. 17(6) [DOI] 10.1371/journal.pone.0268913. [PMID] 35657778.
2022
Clinicians’ Attitudes and Behaviors Towards Communicating Electronically with Patients: A Grounded Practical Theory Approach.
Journal of health communication. 27(2):103-114 [DOI] 10.1080/10810730.2022.2059723. [PMID] 35380099.
2022
Clinicians’ Perceptions of the Benefits and Challenges of Teleoncology as Experienced Through the COVID-19 Pandemic: Qualitative Study
JMIR Cancer. 8(1) [DOI] 10.2196/34895. [PMID] 35142622.
2022
Current Management of Locally Advanced and Metastatic Cervical Cancer in the United States
JCO Oncology Practice. 18(6):417-422 [DOI] 10.1200/op.21.00795.
2022
Factors Associated With Endowed Chair Allocation in Medical Oncology in the United States.
JNCI cancer spectrum. 6(3) [DOI] 10.1093/jncics/pkac036. [PMID] 35657340.
2022
Hematology/Oncology Fellowship Programs’ Participation in the Quality Oncology Practice Initiative
JCO Oncology Practice. [DOI] 10.1200/op.21.00807.
2022
Incidence, Nature, and Consequences of Oncologists’ Experiences With Sexual Harassment
Journal of Clinical Oncology. 40(11):1186-1195 [DOI] 10.1200/jco.21.02574.
2022
Netiquette for social media engagement for oncology professionals.
Future oncology (London, England). 18(9):1133-1141 [DOI] 10.2217/fon-2021-1366. [PMID] 35109663.
2022
Social Media and Professional Development for Oncology Professionals
JCO Oncology Practice. [DOI] 10.1200/op.21.00761.
2021
Anti-NMDAR encephalitis presenting after immature teratoma resection.
BMJ case reports. 14(11) [DOI] 10.1136/bcr-2021-244637. [PMID] 34799390.
2021
Benchmarks for Academic Oncology Faculty
JCO Oncology Practice. 17(3):e440-e444 [DOI] 10.1200/op.20.00020.
2021
Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(10):1165-1184 [DOI] 10.1200/JCO.20.03420. [PMID] 33527845.
2021
Improving secure messaging: A framework for support, partnership & information-giving communicating electronically (SPICE).
Patient education and counseling. 104(6):1380-1386 [DOI] 10.1016/j.pec.2020.11.021. [PMID] 33280967.
2021
Negative affect and the utilization of tobacco treatment among adult smokers with cancer.
Psycho-oncology. 30(1):93-102 [DOI] 10.1002/pon.5543. [PMID] 32885884.
2021
Quality Care in Survivorship: Lessons Learned From the ASCO Quality Oncology Practice Initiative
JCO Oncology Practice. 17(8):e1170-e1180 [DOI] 10.1200/op.21.00290.
2021
Secure Messaging and COVID-19: A Content Analysis of Patient-Clinician Communication During the Pandemic.
Telemedicine journal and e-health : the official journal of the American Telemedicine Association. [DOI] 10.1089/tmj.2021.0316. [PMID] 34767741.
2021
Twenty-first Century Bedside Manner: Exploring Patient-Centered Communication in Secure Messaging with Cancer Patients.
Journal of cancer education : the official journal of the American Association for Cancer Education. 36(1):16-24 [DOI] 10.1007/s13187-019-01592-5. [PMID] 31342283.
2020
A Call to Action: Ethics Committee Roundtable Recommendations for Addressing Burnout and Moral Distress in Oncology.
JCO oncology practice. 16(4):191-199 [DOI] 10.1200/JOP.19.00806. [PMID] 32223701.
2020
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Clinical Cancer Research. 26(5):1009-1016 [DOI] 10.1158/1078-0432.ccr-19-1638.
2020
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Clinical Cancer Research. 26(5):1009-1016 [DOI] 10.1158/1078-0432.ccr-19-1638.
2020
An Implementation Trial to Improve Tobacco Treatment for Cancer Patients: Patient Preferences, Treatment Acceptability and Effectiveness
International Journal of Environmental Research and Public Health. 17(7) [DOI] 10.3390/ijerph17072280. [PMID] 32231062.
2020
Benchmarks for Academic Oncology Faculty
JCO Oncology Practice. [DOI] 10.1200/op.20.00020.
2020
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(10) [DOI] 10.1200/JCO.19.03141. [PMID] 32013670.
2020
Developing and Validating a Computable Phenotype for the Identification of Transgender and Gender Nonconforming Individuals and Subgroups.
AMIA … Annual Symposium proceedings. AMIA Symposium. 2020:514-523 [PMID] 33936425.
2020
Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
Obstetrics & gynecology science. 63(2):205-208 [DOI] 10.5468/ogs.2020.63.2.205. [PMID] 32206661.
2020
Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report
JNCI: Journal of the National Cancer Institute. 112(11):1081-1088 [DOI] 10.1093/jnci/djaa041. [PMID] 32219419.
2020
Palliative Care Scorecard: An Update for the Outpatient Setting.
Journal of palliative medicine. 23(3):306-307 [DOI] 10.1089/jpm.2019.0516. [PMID] 32105557.
2020
Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study.
Obstetrics & gynecology science. 63(2):150-157 [DOI] 10.5468/ogs.2020.63.2.150. [PMID] 32206654.
2020
The Bucket List.
Journal of palliative medicine. 23(3) [DOI] 10.1089/jpm.2019.0435. [PMID] 32105554.
2020
Web‐based LGBT cultural competency training intervention for oncologists: Pilot study results
Cancer. 126(1):112-120 [DOI] 10.1002/cncr.32491.
2019
Application of an objective structured clinical examination to evaluate and monitor intern’s proficiency of hand hygiene and personal protective equipment use in the United States.
Journal of educational evaluation for health professions. 16 [DOI] 10.3352/jeehp.2019.16.31. [PMID] 31614408.
2019
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(10):834-849 [DOI] 10.1200/JCO.18.02037. [PMID] 30702028.
2019
Developing a web-based LGBT cultural competency training for oncologists: The COLORS training
Patient Education and Counseling. 102(5):984-989 [DOI] 10.1016/j.pec.2019.01.006.
2019
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab
. 12(3)
2019
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
BMJ case reports. 12(3) [DOI] 10.1136/bcr-2018-224636. [PMID] 30872333.
2019
Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
Journal of robotic surgery. 13(1):23-33 [DOI] 10.1007/s11701-018-0838-x. [PMID] 29992404.
2018
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(10):2285-2293 [DOI] 10.1158/1078-0432.CCR-17-3055. [PMID] 29500276.
2018
An interactive multimodality curriculum teaching medicine residents about oncologic documentation and billing
.
2018
An Interactive Multimodality Curriculum Teaching Medicine Residents About Oncologic Documentation and Billing.
MedEdPORTAL : the journal of teaching and learning resources. 14 [DOI] 10.15766/mep_2374-8265.10746. [PMID] 30800946.
2018
Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review.
Clinical Medicine Insights. Oncology. 12 [DOI] 10.1177/1179554918779587. [PMID] 29887734.
2018
Impact of Closed Facebook Group Participation on Female Hematology/Oncology Physicians.
Journal of oncology practice. 14(12):e758-e769 [DOI] 10.1200/JOP.18.00448. [PMID] 30537459.
2018
Integrating Social Media in Modern Oncology Practice and Research.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 38:894-902 [DOI] 10.1200/EDBK_204453. [PMID] 30231349.
2018
Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and metaanalysis
Journal of Robotic Surgery. 13(1):23-33
2018
Patients With Cancer and Social Media: Harness Benefits, Avoid Drawbacks.
Journal of oncology practice. [DOI] 10.1200/JOP.18.00367. [PMID] 30383479.
2018
Peripheral T-cell lymphoma mimicking classic Hodgkin’s lymphoma in a patient presenting with fevers of unknown origin.
BMJ case reports. 2018 [DOI] 10.1136/bcr-2017-220858. [PMID] 29420242.
2018
Peripheral T-cell lymphoma mimicking classic Hodgkin’s lymphoma in a patient presenting with fevers of unknown origin
.
2018
Principles for the Oncologist in Caring for Muslim Patients.
Journal of oncology practice. 14(9):521-524 [DOI] 10.1200/JOP.18.00116. [PMID] 30138053.
2018
Rural-urban and racial-ethnic differences in awareness of direct-to-consumer genetic testing.
BMC public health. 18(1) [DOI] 10.1186/s12889-018-5190-6. [PMID] 29471813.
2017
Cancer Survivor’s History and Physical.
Southern medical journal. 110(1):37-44 [DOI] 10.14423/SMJ.0000000000000585. [PMID] 28052173.
2017
Choosing Wisely in Oncology: Are We Ready For Value-Based Care?
Journal of oncology practice. 13(11):e935-e943 [DOI] 10.1200/JOP.2016.019281. [PMID] 28783425.
2017
Implementation of a mock root cause analysis to provide simulated patient safety training.
BMJ open quality. 6(2) [DOI] 10.1136/bmjoq-2017-000096. [PMID] 29450282.
2017
Infusion Room-Based Transition to Practice Model for Teaching Cancer Systemic Therapy Management.
Journal of oncology practice. 13(11):e909-e915 [DOI] 10.1200/JOP.2017.023549. [PMID] 28885879.
2017
Primary Gastric Burkitt Lymphoma: A Rare Cause of Life Threatening Hematemesis
.
2017
Primary gastric Burkitt lymphoma: a rare cause of life-threatening haematemesis.
BMJ case reports. 2017 [DOI] 10.1136/bcr-2017-220313. [PMID] 28830898.
2017
Quality of Social Media and Web-Based Information Regarding Inappropriate Nuclear Cardiac Stress Testing and the Choosing Wisely Campaign: A Cross-Sectional Study
Interactive Journal of Medical Research. 6(1) [DOI] 10.2196/ijmr.7210. [PMID] 28473305.
2017
Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine.
Seminars in hematology. 54(4):198-204 [DOI] 10.1053/j.seminhematol.2017.08.001. [PMID] 29153081.
2017
Social Media for Networking, Professional Development, and Patient Engagement.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. (37):782-787 [DOI] 10.1200/EDBK_180077. [PMID] 30372202.
2017
Social Media for Networking, Professional Development, and Patient Engagement.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 37:782-787 [DOI] 10.14694/EDBK_180077. [PMID] 28561727.
2017
Synchronous Occurrence of Chronic Myeloid Leukemia and Mantle Cell Lymphoma
Case Reports in Hematology. 2017:1-4 [DOI] 10.1155/2017/7815095. [PMID] 28270940.
2016
Chemotherapy in ovarian germ cell tumors: A systematic review
Gynecologic Oncology. 141(3):602-607 [DOI] 10.1016/j.ygyno.2016.02.007.
2016
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(9):987-1011 [DOI] 10.1200/JCO.2015.65.8427. [PMID] 26846975.
2016
Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis.
Leukemia & lymphoma. 57(3):676-84 [DOI] 10.3109/10428194.2015.1102246. [PMID] 26428541.
2016
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Involving the Colon in a Patient With Ulcerative Pancolitis and Polymyositis on Long-Term Methotrexate Therapy.
Gastroenterology research. 9(4-5):83-86 [PMID] 27785332.
2016
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.
ESMO open. 1(5) [PMID] 27843641.
2016
Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.
BMJ case reports. 2016 [DOI] 10.1136/bcr-2016-216228. [PMID] 27440853.
2016
The Intern Handover: the Gap Between Expectations and Performance
Medical Science Educator. 26(4):771-776 [DOI] 10.1007/s40670-016-0312-1.
2015
Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval.
Journal of oncology practice. 11(1):e103-9 [DOI] 10.1200/JOP.2014.001525. [PMID] 25352389.
2015
Outcomes of Definitive Radiation Therapy for Primary Vaginal Carcinoma.
American journal of clinical oncology. 38(6):583-7 [DOI] 10.1097/COC.0000000000000002. [PMID] 24136141.
2015
Rare case of syndrome of inappropriate antidiuretic hormone as the initial presentation of ovarian cancer recurrence.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(9):e48-9 [DOI] 10.1200/JCO.2013.49.8089. [PMID] 24663042.
2015
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Journal of oncology practice. 11(4):332-7 [DOI] 10.1200/JOP.2014.001750. [PMID] 25991639.
2014
Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care.
Journal of oncology practice. 10(4):e247-54 [DOI] 10.1200/JOP.2013.001275. [PMID] 24737876.
2014
Clinical Epigenetic Resensitization of Platinum-Resistant, Recurrent Ovarian Cancer Patients With Sgi-110, a Novel, Second-Generation, Subcutaneously Administered Hypomethylating Agent (Hma)
Cancer Research. 74(19, S) [DOI] 10.1158/1538-7445.AM2014-2320.
2014
Fellowship engagement in hematology/oncology professionalism training.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(11):1164-6 [DOI] 10.1200/JCO.2013.54.6879. [PMID] 24590646.
2014
Florida Initiative for Quality Cancer Care: improvements in breast cancer quality indicators during a 3-year interval.
Journal of the American College of Surgeons. 219(4):638-45.e1 [DOI] 10.1016/j.jamcollsurg.2014.03.063. [PMID] 25086813.
2014
Florida Initiative for Quality Cancer Care: improvements on colorectal cancer quality of care indicators during a 3-year interval.
Journal of the American College of Surgeons. 218(1):16-25.e1 [DOI] 10.1016/j.jamcollsurg.2013.09.008. [PMID] 24275073.
2012
Art of Oncology: The Inadequacy of $20
Journal of Clinical Oncology. 30(28):3558-3559
2012
Characterization and Immunotherapeutic Implication of a Novel Cerebro-Spinal Fluid-Derived Alk-Positive Anaplastic Large Cell Lymphoma Cell Line
Blood. 120
2012
Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(20):2516-21 [DOI] 10.1200/JCO.2011.39.5186. [PMID] 22614993.
2012
Evaluating the quality of colorectal cancer care in the state of Florida: results from the Florida Initiative for Quality Cancer Care.
Journal of oncology practice. 8(4):239-45 [DOI] 10.1200/JOP.2011.000477. [PMID] 23180990.
2012
Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma
Case Reports in Hematology. 2012:1-4 [DOI] 10.1155/2012/954201. [PMID] 22953081.
2012
Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma.
Case reports in hematology. 2012:954201-4 [DOI] 10.1155/2012/954201. [PMID] 22953081.
2012
The inadequacy of 20 dollars.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(28):3558-9 [PMID] 22665538.
2011
Degree of variability in performance on breast cancer quality indicators: findings from the Florida initiative for quality cancer care.
Journal of oncology practice. 7(4):247-51 [PMID] 22043190.
2011
Evaluating the quality of psychosocial care in outpatient medical oncology settings using performance indicators.
Psycho-oncology. 20(11):1221-7 [DOI] 10.1002/pon.1849. [PMID] 20878724.
2011
Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida.
Journal of oncology practice. 7(6):e25-31 [PMID] 22379428.
2010
Head-To-Head Comparisons of Quality of Life Instruments for Young Adult Survivors of Childhood and Adolescent Cancer
Value in Health. 13(3):A45-A46 [DOI] 10.1016/S1098-3015(10)72204-X.
2010
Hepatitis B reactivation and rituximab in the oncology practice.
The oncologist. 15(10):1113-21 [DOI] 10.1634/theoncologist.2010-0106. [PMID] 20930099.
2003
Role of phlebotomy in the management of hemoglobin SC disease: case report and review of the literature.
American journal of hematology. 73(2):121-5 [PMID] 12749014.
1982
Small-cell lung cancer and limbic encephalitis.
Annals of internal medicine. 96(6 Pt 1) [PMID] 6283978.
Clinicians’ Perceptions of the Benefits and Challenges of Teleoncology as Experienced Through the COVID-19 Pandemic: Qualitative Study (Preprint)
. [DOI] 10.2196/preprints.34895.

Grants

Dec 2021 ACTIVE
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)
Role: Principal Investigator
Funding: MERCK AND COMPANY INC
Aug 2020 ACTIVE
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Role: Principal Investigator
Funding: GOG FOUNDATION via ASTRAZENECA ASTRA PHARM
Aug 2020 ACTIVE
Using Electronic Health Records from a Large Clinical Data Research Network to Understand Cancer Burden and Cancer Risks Among Transgender and Gender Nonconforming (TGNC) Individuals
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Mar 2020 ACTIVE
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube or peritoneal primary cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via ASTRAZENECA
Feb 2020 ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
May 2019 ACTIVE
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Role: Principal Investigator
Funding: GOG FOUNDATION via VASCULAR BIOGENICS LTD
Apr 2019 ACTIVE
A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Role: Principal Investigator
Funding: GOG FOUNDATION via NOVARTIS PHARMACEUTICALS CORP
Mar 2019 ACTIVE
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Mar 2019 ACTIVE
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Mar 2019 ACTIVE
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Nov 2018 ACTIVE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO via TESARO INC
Sep 2018 ACTIVE
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Sep 2018 – Feb 2019
ET-CTN with Phase 2 Emphasis
Role: Other
Funding: UNIV OF PITTSBURGH via NATL INST OF HLTH NCI
Jun 2018 – May 2022
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Role: Principal Investigator
Funding: ELI LILLY AND CO
Sep 2017 – Jun 2019
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Sep 2017 – Jun 2021
Florida Cancer ReTOOL Program for Underrepresented Minority Students
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Apr 2017 – Feb 2018
A multiple patient early access program for olaparib tablets for the maintenance treatment following response (complete response or partial response) to platinum-based chemotherapy in patients with platinumsensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP
May 2016 – May 2021
ADU-CL-11: A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Role: Principal Investigator
Funding: ADURO BIOTECH INC
May 2016 – May 2019
A PHASE 1/2 OPEN LABEL SAFETY AND EFFICACY EVALUATION OF CRS-207 IN COMBINATION WITH EPACADOSTAT IN ADULTS WITH……
Role: Principal Investigator
Funding: ADURO BIOTECH INC
Apr 2016 – Feb 2019
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
Feb 2016 – Aug 2019
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Feb 2016 – Feb 2019
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Oct 2015 – Jun 2018
ASCO-sponsored cancer interest group
Role: Principal Investigator
Funding: AMER SOC FOR CLINICAL ONCOLOGY
Jul 2015 ACTIVE
Florida Academic Cancer Center Alliance Seed Grants
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Sep 2014 – Aug 2019
Florida Minority Cancer Research and Training Center: Feasibility Studies
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Mar 2014 – Mar 2019
A RANDOMIZED PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN/METFORMIN (NSC#91485) VERSUS PACLITAXEL/CARBOPLATIN/PLACEBO AS INITIAL THERAPY FOR MEASURABLE STAGE III OR IVA, STAGE IVB, OR RECURRENT ENDOMETRIAL CANCER
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH
Feb 2013 – Jan 2018
A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer
Role: Principal Investigator
Funding: ASTEX PHARMACEUTICALS
Dec 2012 – Aug 2020
A PHASE 3, RANDOMIZED DOUBLE BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE..
Role: Principal Investigator
Funding: MILLENNIUM PHARMACEUTICAL
Jan 2011 ACTIVE
OPERATING ACCOUNT-HEMATOLOGY/ONCOLOGY
Role: Principal Investigator
Funding: UNIV OF FLORIDA

Education

Fellowship, Hematology and Oncology
2005-2008 · University of Florida
Chief Resident, Internal Medicine
2004-2005 · University of Florida
Residency – Internal Medicine
2001-2004 · University of Florida
Medical Degree
2001 · University of Miami
Bachelor of Science
1994 · University of Florida

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Addresses:
Business Mailing:
PO Box 100278
GAINESVILLE FL 32610
Business Street:
M401A, MEDICAL SCIENCE BUILDING
GAINESVILLE FL 326100001